Skip to main content

Table 3 SPCs status of TDF/FTC and access to PrEP

From: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

TDF/FTC

The Netherlands

Belgium

UK

Denmark

Norway

France

Germany

Switzerland

Ireland

SPC

Rejected

Preliminary injunction rejected

Preliminary injunction rejected

Maintained

No information

Revoked

Revoked

Maintained

Preliminary injunction granted

Prices listed

Average retail price [107]

Ex-factory price (excluding taxes) [108]

Reference price [109]

Retail price [110]

Maximum retail price [111]

Ex-factory price (excluding taxes) [112]

Retail price [113, 114]

Reference price [115]

Retail price [116]

Truvada price

344

380

402

1110

550

295

819

773

400

Cheapest available generic price

48

N/A

N/A

N/A

243

139

53

N/A

85

Originator - generic price difference

86%

N/A

N/A

N/A

56%

53%

94%

N/A

79%

Generic available on the market

Yes [117]

No [103]

No [118]

No [99]

Yes [111]

Yes [119]

Yes [120]

No [115]

Yes [121]

Reimbursement

Yes [122]

Yes [123]

No [124, 125]

No information

Yes [126]

Yes [119]

Pending [127]

No [128]

No [129]

  1. Prices are in euro for 30 oral doses of TDF/FTC on 23 July 2018. Local currencies were converted to euro on 23 July 2018 [130]